MIRM
Mirum Pharmaceuticals
November 4, 2026 · market open
- Rarity
- 1.64
- Peak move
- +9.92%
- Float cap
- $3.7B
Still running — rarity and peak move can only rise from here.
Mirum Pharmaceuticals is a commercial-stage rare disease drugmaker focused on rare liver and rare genetic conditions. It sells LIVMARLI for Alagille syndrome and PFIC, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis to specialty hepatologists, geneticists and treatment centers in the United States, Europe and other markets. Its pipeline includes volixibat, brelovitug, zilurgisertib and MRM-3379.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.